Benzinga's Top #PreMarket Losers

NPS Pharmaceuticals

fell 10.70% to $29.20 in pre-market trading. The FDA has voted 8-5 in favor of NPS Pharmaceuticals' Natpara. Achillion Pharmaceuticals

shares slipped 3.28% to $11.78 in pre-market trading after falling 3.87% on Friday. Cree

shares dipped 2.75% to $41.50 in pre-market trading. Goldman Sachs downgraded from Buy to Neutral and lowered the target price from $60 to $48. Symantec

dropped 2.16% to $24.00 in pre-market trading. Analysts at RBC Capital downgraded Symantec from Outperform to Sector Perform. Gilead Sciences

shares fell 1.41% to $102.20 in pre-market trading after the company reported that it has signed licensing agreements with seven India-based generic pharmaceutical manufacturers to expand access to its hepatitis C treatments in developing countries.